Bibliography
- Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; published online as, doi:10.1016/S0140-6736(13)62422-8
- Piccart-Gebhart M, Holmes AP, De Azambuja E, et al. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06) [abstract S1-01]. San Antonio Breast Cancer Symposium; 2013
- Slamon DJ, Swain SM, Geyer CE, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab +/- bevacizumab in patients with HER2-positive, node-positive or high risk node negative breast cancer [abstract S1-03]. San Antonio Breast Cancer Symposium; 2013
- O'Sullivan CC, Holmes E, Spielmann M, et al. The prognosis of small HER2+ breast cancers: a meta-analysis of the randomized trastuzumab trials [abstract S6-03]. San Antonio Breast Cancer Symposium; 2013
- Tolaney SM, Barry WT, Dang CT, et al. A Phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative HER2+ breast cancer [abstract S1-04]. San Antonio Breast Cancer Symposium; 2013
- Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683-92
- Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) [abstract S5-01]. San Antonio Breast Cancer Symposium; 2013
- Rugo HS, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL [abstract S5-02]. San Antonio Breast Cancer Symposium; 2013
- Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013;13:1187-96
- Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013; published online as, doi:10.1016/S0140-6736(13)62292-8
- Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91
- Santini D, Galluzzo S, Zoccoli A, et al. New molecular targets in bone metastases. Cancer Treat Rev 2010;36(Suppl 3):S6-S10
- Coleman R, Gnant M, Paterson A, et al. Effects of bisphosphonates treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials [abstract S4-07]. San Antonio Breast Cancer Symposium; 2013
- Tomasello G, de Azambuja E, Dinh P, et al. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008;8:1883-90
- Von Minckwitz G, Schneeweiss A, Salat C, et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). ASCO Meeting Abstracts 2013;31:1004
- Prat A, Adamo B, Cheang MC, et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013;18:123-33
- Decensi A, Dunn BK, Puntoni M, et al. Exemestane for breast cancer prevention: a critical shift? Cancer Discov 2012;2:25-40
- Chlebowski RT, Kim JS, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila) 2014. [Epub ahead of print]
- Henry NL, Kidwell K, Hayes DF, et al. Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy [abstract S3-02]. San Antonio Breast Cancer Symposium; 2013
- Irwin ML, Cartmel B, Gross C, et al. Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: the hormones and physical exercise (HOPE) study [abstract S3-03]. San Antonio Breast Cancer Symposium; 2013